Targeting Immune Checkpoints in Melanoma: An Update

References

• Wolchok JD . Scientific American310 , 40 – 45 ( 2014 ).
   PubMedGoogle Scholar
• Siegel RL , MillerKD , JemalA . Cancer statistics 2015 . CA Cancer J. Clin.65 , 5 – 29 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Erdmann F , Lortet-TieulentJ , SchüzJet al. International trends in the incidence of malignant melanoma 1953–2008: are recent generations at higher or lower risk? Int. J. Cancer 132 ( 2 ), 385 – 400 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gorantla VC , KirkwoodJM . State of melanoma: an historic overview of a field in transition . Hematol. Oncol. Clin. North Am.28 ( 3 ), 415 – 435 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Miller AJ , MihmMC . Melanoma . N. Engl. J. Med.355 , 51 – 65 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hodi FS , O'DaySJ , McDermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma . N. Engl. J. Med.363 ( 8 ), 711 – 723 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Robert C , ThomasL , BondarenkoIet al. ipilimumab plus dacarbazine for previously untreated metastatic melanoma . N. Engl. J. Med.364 , 2517 – 2526 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Robert C , LongGV , BradyBet al. Nivolumab in previously untreated melanoma without BRAF mutation . N. Engl. J. Med.372 , 320 – 330 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Maio M , GrobJJ , amdalSet al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a Phase III trial . J. Clin. Oncol.33 ( 10 ), 1191 – 1196 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Curiel TJ . Historical perspectives and current trends in cancer immunotherapy . In : Cancer Immunotherapy: Paradigms, Practice and Promise . CurielTJ ( Ed. ). Springer , New York, NY, USA ( 2012 ).
   Google Scholar
• Coley WB . Contribution to the knowledge of sarcoma . Ann. Surg.14 , 199 – 220 ( 1891 ).
   PubMedGoogle Scholar
• Burnet FM . The concept of immunological surveillance . Prog. Exp. Tumor Res.13 , 1 – 27 ( 1970 ).
   PubMed Web of Science ®Google Scholar
• Dunn GP , BruceAT , IkedaHet al. Cancer immunoediting: from immunosurveillance to tumor escape . Nat. Immunol.3 ( 11 ), 991 – 998 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA . Hallmarks of cancer: the next generation . Cell144 ( 5 ), 646 – 674 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chen DS , MellmanI . Oncology meets immunology: the cancer-immunity cycle . Immunity39 ( 1 ), 1 – 10 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• De Visser KE , EichtenA , CoussensLM . Paradoxical roles of the immune system during cancer development . Nat. Rev. Cancer6 ( 1 ), 24 – 37 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mellman I , CoukosG , DranoffG . Cancer immunotherapy comes of age . Nature480 ( 7378 ), 480 – 489 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Peggs KS , QuezadaSA , KormanAJ , AllisonJP . Principles and use of anti-CTLA-4 antibody in human cancer immunotherapy . Curr. Opin. Immunol.18 , 206 – 213 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Robert C , GhiringhelliF . What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?Oncologist14 , 848 – 861 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ott PA , HodiFS , RobertC . CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients . Clin. Cancer Res.19 ( 19 ), 5300 – 5309 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Greenwald RJ , FreemanGJ , SharpeAH . The B7 family revisited . Annu. Rev. Immunol.23 , 515 – 548 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Linsley PS , LedbetterJA . The role of the CD28 receptor during T cell responses to antigen . Annu. Rev. Immunol.11 , 191 – 212 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Wang L , RubinsteinR , LinesJLet al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses . J. Exp. Med.208 ( 3 ), 577 – 592 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Flies DB , WangS , XuH , ChenL . Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models . J. Immunol.187 ( 4 ), 1537 – 1541 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Flies DB , HanX , HiguchiTet al. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity . J. Clin. Invest.124 ( 5 ), 1966 – 1975 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Watts TH . TNF/TNFR family members in costimulation of T cell responses . Annu. Rev. Immunol.23 , 23 – 68 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• O'Day SJ , HamidO , UrbaWJ . Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies . Cancer110 , 2614 – 2627 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ribas A , KeffordR , MarshallMAet al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma . J. Clin. Oncol.31 ( 5 ), 616 – 622 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Robert C , RibasA , WolchokJDet al. Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase I trial . Lancet384 , 1109 – 1117 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Weber JS , MinorD , D'AngeloSPet al. A Phase III randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma with prior anti-CTLA-4 therapy . Presented at : 2014 European Society of Medical Oncology Congress . Madrid, Spain . 26–30 September 2014 ( Abstract 728 ).
   Google Scholar
• Robert C , SchachterJ , LongGVet al. Pembrolizumab versus ipilimumab in advanced melanoma . N. Engl. J. Med. doi:10.1056/NEJMoa1503093 ( 2015 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Postow MA , ChesneyJ , PavlickACet al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma . N. Engl. J. Med. doi:10.1056/NEJMoa1414428 ( Epub ahead of print ) ( 2015 ).
   Web of Science ®Google Scholar
• Wolchok JD , WeberJS , HamidOet al. ipilimumab efficacy and safety in patients with melanoma: a retrospective analysis of HLA subtype from four trials . Cancer Immun.10 , 9 – 14 ( 2010 ).
   PubMedGoogle Scholar
• Shadendorf D , HodiFS , RobertCet al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma . J. Clin. Oncol. doi:10.1200/JCO.2014.56.2736 ( 2015 ) ( Epub ahead of print ).
   Google Scholar
• Wolchok JD , NeynsB , LinetteGet al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase 2, dose-ranging study . Lancet Oncol.11 ( 2 ), 155 – 164 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Eggermont AM , Chiarion-SileniV , GrobJJet al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 Phase III trial . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract LBA9008 ( 2014 ).
   Google Scholar
• Freeman GJ , LongAJ , IwaiYet al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation . J. Exp. Med.192 ( 7 ), 1027 – 1034 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Nishimura H , HonjoT . PD-1: an inhibitory immunoreceptor involved in peripheral tolerance . Trends Immunol.22 ( 5 ), 265 – 268 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Carter L , FouserLA , JussifJet al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2 . Eur. J. Immunol.32 ( 3 ), 634 – 643 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Latchman Y , WoodCR , ChernovaTet al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation . Nat. Immunol.2 ( 3 ), 261 – 268 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS , BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer . N. Engl. J. Med.366 , 2443 – 2454 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Topalian SL , SznolM , McDermottDFet al. Survival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab . J. Clin. Oncol.32 , 1020 – 1030 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hodi FS , SznolM , KlugerHMet al. Long-term survival of ipilimumab-naive patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a Phase I trial . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract 9002 ( 2014 ).
   PubMedGoogle Scholar
• Hamid O , RobertC , DaudAet al. Safety and tumor responses with Iambrolizumab (anti-PD-1) in melanoma . N. Engl. J. Med.369 , 134 – 144 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ribas A , HodiFS , KeffordRet al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients with melanoma . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract LBA9000 ( 2014 ).
   Google Scholar
• Atkins MB , KudchadkarRR , SznolMet al. Phase II, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract 9001 ( 2014 ).
   Google Scholar
• Herbst RS , GordonMS , FineGDet al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors . J. Clin. Oncol.31 ( Suppl. ), Abstract 3000 ( 2013 ).
   Google Scholar
• Herbst RS , SoriaJC , KowanetzMet al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients . Nature515 ( 7528 ), 563 – 567 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hamid O , SosmanJA , LawrenceDPet al. Clinical activity, safety, and biomarkers with MPDL32801A, an engineered anti-PDL1 antibody in patients with locally advanced or metastatic malignant melanoma . J. Clin. Oncol.31 ( Suppl. ), Abstract 9010 ( 2013 ).
   PubMedGoogle Scholar
• Lutzky J , AntoniaSJ , Blake-HaskinsAet al. A Phase I study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract 3001 ( 2014 ).
   Google Scholar
• Weber JS , KahlerKC , HauschildA . Management of immune-related adverse events and kinetics of response with ipilimumab . J. Clin. Oncol.30 , 2691 – 2697 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Postow MA , CallahanMK , WolchokJD . Immune checkpoint blockade in cancer therapy . J. Clin. Oncol.33 ( 17 ), 1974 – 1980 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wolchok JD , KlugerH , CallahanMKet al. Nivolumab plus ipilimumab in advanced melanoma . N. Engl. J. Med.369 , 122 – 133 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb: Yervoy (ipilimumab): Immune-mediated adverse reaction management guide . www.hcp.yervoy.com/pdf/rems-managementguide.pdf .
   Google Scholar
• Min L , HodiFS , Giobbie-HurderAet al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis. A retrospective cohort study . Cancer Res.21 ( 4 ), 749 – 755 ( 2014 ).
   Web of Science ®Google Scholar
• Downey SG , KlapperJA , SmithFOet al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade . Clin. Cancer Res.13 , 6681 – 6688 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ascierto PA , SimeoneE , SileniVCet al. Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort . J. Transl. Med.12 , 116 – 122 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Saenger YM , WolchokJD . The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases . Cancer Immun.8 , 1 – 7 ( 2008 ).
   PubMedGoogle Scholar
• Wolchok JD , HoosA , O'DaySet al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria . Clin. Cancer Res.15 , 7412 – 7420 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP , BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) . Eur. J. Cancer45 ( 2 ), 228 – 247 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Wolchok JD , WeberJS , MaioMet al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in Phase II clinical trials . Ann. Oncol.24 , 2174 – 2180 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Attia P , PhanGQ , MakerAVet al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 . J. Clin. Oncol.23 , 6043 – 6053 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Gogas H , IoannovichJ , DafniUet al. Prognostic significance of autoimmunity during treatment of melanoma with interferon . N. Engl. J. Med.354 , 709 – 718 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Teulings H , LimpensJ , JansenSNet al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis . J. Clin. Oncol.33 ( 7 ), 773 – 781 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ku GY , YuanJ , PageDBet al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival . Cancer116 , 1767 – 1775 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Postow MA , ChasalowSD , YuanJet al. Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3 mg/kg) . J. Clin. Oncol.30 ( Suppl. ), Abstract 8575 ( 2012 ).
   Google Scholar
• Schindler K , HarmankayaK , PostowMAet al. Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti-CTLA-4 antibody . J. Clin. Oncol.31 ( Suppl. ), Abstract 9024 ( 2013 ).
   Google Scholar
• Wang W , YuD , SarnaikAAet al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment . J. Transl. Med.10 , 146 – 157 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chakravarti N , GlitzaIC , TrinhVAet al. Biomarker analysis predicts antitumor activity of ipilimumab therapy in patients with refractory metastatic melanoma . Cancer Res.74 , CT332 ( 2014 ).
   Web of Science ®Google Scholar
• Taube JM , KleinAP , BrahmerJRet al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy . Clin. Cancer Res.20 , 5064 – 5074 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Weber JS , KudchadkarRR , YuBet al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma . J. Clin. Oncol.31 , 4311 – 4318 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Madore J , VilainRE , MenziesAMet al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials . Pigment Cell Melanoma Res.28 ( 3 ), 245 – 253 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• van Rooij N , van BuurenMM , PhilipsDet al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma . J. Clin. Oncol.31 ( 32 ), e439 – e442 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Snyder A , MakarovV , MerghoubTet al. Exome sequencing reveals a genetic basis underlying clinical response to CTLA-4 blockade . N. Engl. J. Med.371 , 2189 – 2199 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Robert L , HarviewC , mersonRet al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes . Oncoimmunology3 , e29244 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tumeh PC , HarviewCL , YearleyJHet al. PD-1 blockade induces responses by inhibiting adaptive immune resistance . Nature515 ( 7528 ), 568 – 571 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Curti BD , Kovacsovics-BankowskiM , MorrisNet al. OX40 is a potent immune-stimulating target in late-stage cancer patients . Cancer Res.73 , 7189 – 7198 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sznol M , HodiFS , MargolinKet al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) . J. Clin. Oncol.26 ( 15 Suppl. ), 3007 ( 2008 ).
   Google Scholar
• Sznol M , KluggerHM , CallahanMKet al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract LBA9003 ( 2014 ).
   Google Scholar
• Liu BL , RobinsonM , HanZQet al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties . Gene Ther.10 ( 4 ), 292 – 303 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Toda M , MartuzaRL , RabkinSD . Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor . Mol. Ther.2 ( 4 ), 324 – 329 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Kaufman HL , AndtbackaRHI , CollichioFAet al. Primary overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract 9008a ( 2014 ).
   Google Scholar
• Andtbacka RHI , CollichioFA , AmatrudaTet al. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) . J. Immunother. Cancer2 ( Suppl. 3 ), P263 ( 2014 ).
   Google Scholar
• Puzanov I , MilhemMM , AndtbackaRHIet al. Primary analysis of a Phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract 9029 ( 2014 ).
   PubMedGoogle Scholar
• Hodi S , LeeSJ , McDermottDFet al. Multicenter, randomized Phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 . J. Clin. Oncol.31 ( Suppl. ), Abstract CRA9007 ( 2013 ).
   PubMedGoogle Scholar
• Kudchadkar RR , GibneyGT , DormanDet al. A Phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma . J. Clin. Oncol.32 ( Suppl. 5 ), Abstract 9098 ( 2014 ).
   Google Scholar
• Agarwala SS . Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma . Melanoma Res.20 ( 1 ), 1 – 10 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Maker AV , PhanGQ , AttiaPet al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte associated antigen 4 blockade and interleukin 2: a Phase I/II study . Ann. Surg. Oncol.12 ( 12 ), 1005 – 1016 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J , GeM , KaoJet al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies . Cancer Res.69 ( 6 ), 2514 – 2522 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ribas A , HodiFS , CallahanMet al. Hepatotoxicity with combination of vemurafenib and ipilimumab . N. Engl. J. Med.368 , 1365 – 1366 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Puzanov I , CallahanMK , LinetteGPet al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) . J Clin. Oncol.32 ( Suppl. 5s ), Abstract 2511 ( 2014 ).
   PubMedGoogle Scholar
• Postow MA , CallahanMK , BarkerCAet al. immunologic correlates of the abscopal effect in a patient with melanoma . N. Engl. J. Med.366 , 925 – 931 ( 2012 ).
   PubMed Web of Science ®Google Scholar